As of Mar 24
| 0.00 / 0.00%|
The 10 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 31.00, with a high estimate of 60.00 and a low estimate of 22.00. The median estimate represents a +22.05% increase from the last price of 25.40.
The current consensus among 11 polled investment analysts is to Buy stock in Acorda Therapeutics Inc. This rating has held steady since March, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.